* Different customer tiers. Basic screening for all customers would involve recording and verifying customer identity and checking against existing government watch lists. For customers intending to use benchtops to synthesize sequences of concern, the intended use should be scoped and clarified with the permission of a biosafety authority. This may also be integrated with a certificate system such as the SecureDNA exemption token system. * Unambiguous criteria for “legitimate customer” and “legitimate use.” These criteria should be developed in conjunction with industry partners and may consider an approach of whitelisting particular use cases and customers and black-listing others while using a human to adjudicate edge cases. * Incentives for screening. This can be preferential purchasing agreements for vendors who screen but also enforcement mechanisms against manufacturers who do not screen. * A reagent track and trace system. Similar to the Drug Supply Chain Security Act for pharmaceuticals. This would involve maintaining detailed records of each transfer in the supply chain, such as the date and time of transfer, sender and recipient information, as well as digital signatures or other secure authentication methods for each transfer to ensure accountability.